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Abstract
CYP4F (Cytochrome P4504F) enzymes metabolize endogenous molecules
including leukotrienes, prostaglandins and arachidonic acid. The involvement of
these endogenous compounds in inflammation has led to the hypothesis that
changes in the inflamed tissue environment may affect the expression of CYP4Fs
during the pro-inflammatory state, which in turn may modulate inflammatory
conditions during the anti-inflammatory state. We demonstrated that inflamed
tissues have different levels of CYP4F isoform expression profiles in a number of
human samples when compared to the average population. The CYP4F isoform
expression levels change with the degree of inflammation present in tissue. Further
investigation in cell culture studies revealed that inflammatory cytokines, in
particular TNF-!, play a role in regulating the expression of the CYP4F family. One
of the isoforms, CYP4F11, had different characteristics than that of the other five
CYP4F family members. CYP4F11 metabolizes xenobiotics while the other
isoforms metabolize endogenous compounds with higher affinity. CYP4F11 also
was expressed at high quantities in the brain, and was up-regulated by TNF-!,
while the other isoforms were not expressed at high quantities in the brain and
were down-regulated by TNF-!. We identified the AP-1 protein of the JNK pathway
as the signaling protein that causes significant increase in CYP4F11 expression.
v

Since TNF-! stimulation causes a simultaneous activation of both JNK pathway
and NF-"B signaling, we investigated further the role that NF-"B plays on
expression of the CYP4F11 gene. We concluded that although there is a significant
increase in CYP4F11 expression in the presence of TNF-!, the activation of NF-"B
signaling inhibits CYP4F11 expression in a time dependent manner. The
expression of CYP4F11 is only significantly increased after 24 hours of treatment
with TNF-!; at shorter time points NF-"B signaling overpowers the JNK pathway
activation. We believe that these findings may in the future lead to improved drug
design for modulating inflammation.
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Chapter One: Introduction
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Cytochrome P450 Superfamily
Discovery, Nomenclature, Evolution
The Cytochrome P450 (CYPs) family of hemoproteins is the largest and
most functionally diverse superfamilies of enzymes. They are responsible for the
oxidation, peroxidation, and reductive metabolism of many endogenous
compounds such as fatty acids, prostaglandins, leukotrienes, steroids and biogenic
amines. A great number of the CYPs are also able to metabolize xenobiotics
including drugs, environmental pollutants, natural plant products, and alcohols [1].
The ability for mammalian tissues to oxidize non-polar xenobiotics was known in
the early 1950’s, however the enzyme or enzymes responsible for the catalysis
were not [2]. In 1958 studies from pig and rat microsomal protein fractions noted
the existence of a spectral absorbance peak (Soret peak) at 450nm in the
presence of carbon monoxide [2]; this was later identified as a P450 hemoprotein
[3]. This unique spectral absorbance peak is where CYPs obtain their name.
Human CYPs are named using the following system: CYP, denoting
cytochrome P450, an Arabic number designating the P450 family, a letter
indicating the subfamily when there are two or more subfamilies known, and then
followed by an Arabic numeral representing the individual gene [1]. For example:
CYP4F11. If a CYP sequence displays amino acid identity that is greater than 40%
they are grouped into the same family [2]. If those sequences are greater than 55%
identical then they are placed in the same subfamily, followed by a sequence
identity of 97% or higher resulting in alleles [2].
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The human genome encodes 57 CYP proteins (http://drnelson.utmem.edu/
CytochromeP450.html). A recent survey performed by the Guengerich group
classified fifteen CYPs as being involved in the metabolism of xenobiotic
chemicals, fourteen being involved in the metabolism of sterols; four that oxidize
fat-soluble vitamins; and nine involved in the metabolism of fatty acids and
eicosanoids in which for the topic of my dissertation the CYP4F family resides. The
remaining fifteen CYPs substrates are undesignated [4].
The first CYP is believed to have been present as early as three and a half
billion years ago [2]. The thought is that as the earth’s atmosphere accumulated
more molecular oxygen CYPs were recruited to protect life forms from oxygen
toxicity. There was then a switch wherein metabolism of toxic plant allelochemicals,
xenobiotics and, thereby, modern pharmaceuticals arose as an important feature of
the cytochrome P450 gene superfamily [2]. It is hypothesized that during evolution
there was a “plant-animal warfare,” whereby animals evolved new P450s to
synthesize the toxic phytoalexins produced by plants [5]. It is this evolution of CYP
dependent metabolism of plant metabolites by insects and mammals that is most
likely linked to present day role of CYPs ability to detoxify pollutants, toxins and
pharmaceuticals [2].
Monoxygenase system
Cytochrome P450s main function is to activate molecular oxygen to yield a
reactive species that can attack chemical sites to form hydroxyl groups into
structures as unreactive as hydrocarbon chains and aromatic rings [6]. There are
three major components to the monoxygenase enzyme system: 1) Heme protein,
3

CYP, 2) the flavoprotein, NADPH CYP-reductase and 3) phospholipids [7]. The
reductase is needed to transfer two electrons to the CYP thus providing reducing
equivalents to the heme iron for reduction of molecular oxygen and product
formation during catalysis [4]. The basic reaction takes one molecular oxygen atom
and inserts it into a substrate (SH), the second atom being reduced to water:
The CYP catalytic cycle follows steps shown in Figure 1.1 [4]. The main steps are

NAD(P)H + O2 + SH + H+

NAD(P)+ + SOH + H2O

as follows:
1.

Substrate binds to CYP recognition site

2.

An electron from NADPH via Cytochrome P450 reductase reduces heme
ferric iron

3.

Oxygen binds the ferrous iron

4.

Second electron forms the peroxy iron complex

5.

Cleavage of the O-O bond forming H2O and a reactive iron-oxo complex

6.

Oxygen is then transferred to the bound substrate

7.

Product is released

4

Figure 1.1 Cyctochrome P450 catalytic cycle. The Cytochrome
P450 enzymes act as monoxygenase systems, where molecular O2
is used to oxidize lipophilic substrates (RH). This figure is adapted
from the PROMISE mirror database (website: http://
metallo.scripps.edu/PROMISE/P450.html)
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Hepatic and extra hepatic metabolism
Even though there are many different families of CYPs the conventional
wisdom has been that xenobiotics are mainly metabolized by the CYP families
CYP1, CYP2, and CYP3 [8]. With current research in our laboratory we have also
found that one isoform of the CYP4F family is as good at metabolizing xenobiotics
as CYP3A4 the CYP responsible for metabolizing about 30% of clinically available
drugs [7]. In mammals, the liver is the major organ with cytochrome P450
expression and activity. However, the presence of phase I metabolizing enzymes,
which include CYPs [9],[10],[11] along with phase II metabolizing enzymes [9], [11],
and phase III transporters [12],[13], are also expressed across many other tissues.
This distribution of metabolizing enzymes also makes them promising candidates
for drug delivery. However, most of the studies conducted on phase I CYP
enzymes are focused mainly on the CYP families 1,2, and 3, and since our
laboratory has uncovered the ability of CYP4F11 to metabolize drugs, we have
focused thisP450s research to examine the distribution of the 4F family in the
human body and how the CYP4Fs are regulated.
Cytochrome P450s as therapeutic targets
Currently there are several CYPs that have been targets for drug design,
chiefly CYP19A1 and CYP5A1. CYP19A1 or aromatase is responsible for a key
step in the biosynthesis of estrogens, and it is this function that drug design has
been utilized to inhibit its function [14]. Estrogen production is a component of
some cancer processes and other diseases and thus the use of this CYP as a drug
target has had a great affect on the treatment of estrogen-related diseases.
6

Furthermore, CYP5A1 or thromboxane A synthase specializes in converting
prostaglandin H2 to thromboxane A2, a potent vasoconstrictor and inducer of
platelet aggregation [15]. Drugs designed as thromboxane A synthase inhibitors
are valuable as antithrombotic and antihypertensive drugs [16]. For most other
CYPs the attempts to inhibit their activities to achieve either greater drug
availability, as in the case of CYP3A4 substrates, or to inhibit the progression of a
known function, such as synthesis of arachidonic acid, is still in the beginning
stages [7]. Nevertheless, since the goal is to serve people with an effective
treatment for disease, knowledge of the function, regulation and expression of
cytochrome P450s as they regulate drug availability and inflammation is important
in obtaining that goal.
Inflammation and Cytochrome P450s
Another complication for drug design is the fact that during many diseases
and infections the normal host defense mechanism is activated and mediators of
inflammation are present throughout the body. This is a problem because
inflammation modifies the expression, activity, and functions of drug-metabolizing
enzymes and drug transporters [17]. Mainly, the inflammatory stimuli cause
decreased catalytic abilities of CYPs which could lead to the dose-dependent drug
toxicity associated with impaired drug clearance [18]. Thus, understanding the role
inflammation plays in regulating CYPs is very important for clinical drug therapy in
disease states. During an inflammatory response the liver’s ability to handle drugs
is not optimal and the expression of CYP genes are down-regulated at the
transcript levels [18], which leads to the observed decreased catalytic abilities.
7

Carcillo et al. showed that children with sepsis had a twofold reduction in antipyrine
clearance compared to controls [19]. This study shows the importance of
inflammatory mediator regulation of a number of CYPs and how marker
inflammatory mediators may play a role. In their study they focused on the cytokine
Interleukin-6 (IL-6) and nitric oxide (NO) [19]. They concluded that for drugs
metabolized by CYPs there needs to be a reevaluation of the use of standard drug
dosage schedules especially for patients with sepsis, which show a high increase
in host defense inflammation measures [19]. Figure 1.2 is a pathway proposed for
the loss of catalytic activity during an inflammatory response [20].
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Figure 1.2. Modified proposed pathway for the loss in drug
metabolism during an inflammatory response. Diseases cause
an inflammatory response that causes the release of cytokines from
macrophages, and monocytes which lead to a modified
transcription profile of genes that are active in the liver. These
changes down-regulate most of the CYP genes expressed in the
liver. Which ultimately lead to a low drug clearance and high
chance of drug toxicity [20].

9
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An important nuclear transcription factor in the mediation of inflammation is
the nuclear transcription factor-kappa B (NF-!B). Two classic cytokines can lead to
the release of NF-!B, interleukin-1# (IL-1#) and tumor necrosis factor-alpha (TNF"); stimulation of NF-!B by these two cytokines is considered the classical pathway
[21]. This current research project focuses mainly on these cytokines because of
their up-regulation during normal host defense processes, and their down stream
activation of NF-!B, which also serves as an important transcription factor in the
regulation of CYPs. NF-!B regulates over 200 genes involved in a plethora of
cellular processes [22],[23],[24],[25]. NF-!B is composed of hetero- or homodimers of five members, p52, p50, p65 (RelA), RelB, and c-Rel and each unit has
its own biological activity [21]. NF-!B has been reported to mechanistically regulate
the transcription of CYPs either by indirectly regulating the gene through mutual
repression between NF-!B and many other nuclear receptors, or by directly
binding to the response element of the CYP gene [22]. Another mechanism that
has also been reported is the ability of NF-!B to affect the stability of the CYP on
the protein level [26], [22]. The mechanistic capabilities of NF-!B and its ability to
regulate CYPs are important in the scheme of understanding the expression
response of CYPs during an inflammatory response so that drug design and
patient care can be improved.
Most current studies examining changes observed in CYP expression
during normal host defense mechanism response have been performed on CYP
Families 1,2 and 3 [20],[27],[19]. Our laboratory is working on the effects that
inflammatory mediators and thus host response mediators have on the CYP4F
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family and the significance of this information for the future of drug design and
resolution of inflammation.
Cytochrome P450 4F subfamily
Function
The Cytochrome P450 4F (CYP4F) family was first discovered by two
different groups as part of an effort to define an inactivation pathway for leukotriene
B4 (LTB4), a powerful mediator of inflammation [28],[29]. The CYP4Fs catalyze $
and $-1-hydroxylation reactions; it is this reaction that aids in the removal of LTB4,
(Figure 1.3) a prominent proinflammatory signal which, when left unregulated, can
cause secondary harmful effects [30].
There are seven CYP4F isoforms presently known to be expressed in
humans: CYP4F2, CYP4F3A, CYP4F3B, CYP4F8, CYP4F11, CYP4F12 and
CYP4F22. Table 1.1 shows each family members’ characteristics. It is important to
note that of the seven isoforms the primary drug metabolizer is CYP4F11 [31].
However, it is the ability of most of the family members to metabolize multiple
mediators of inflammation and regulatory processes such as LTB4, prostaglandins
and arachidonic acid (AA) that has been the focus of the current project on the
regulation of these important enzymes.
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Figure 1.3 Enzymatic pathway for metabolism of
LTB4[32]. After Leukotriene B4 is produced CYP4Fs are
able to start the deactivation process of LTB4 by
hydroxylation.
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Table 1.1 CYP4F subfamily members and their respective
known substrates
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Expression and Distribution
There have been a few reports about the location of many different CYP4Fs
throughout the human body. CYP4F2 was shown to be expressed in liver, kidney,
skin and several other tissues and tumors [32],[33]. CYP4F3 was shown to be
expressed in the human liver, while CYP4F8 was shown to be present in seminal
vesicles, epidermis, hair follicles, sweat glands, proximal renal tubules, and
epithelial linings of the gut and urinary tract [34]. CYP4F11 has been localized to
the human liver, kidney, heart, brain and skeletal muscle [35]. Lastly, CYP4F12 has
been reported to be expressed in the liver, kidney, seminal vesicles, small
intestine, prostate gland and ovarian follicles [36],[37],[38]. While the presence of
these isoforms have been identified in a great variety of human tissues, there has
not been a complete analysis of the expression level of each isoform of the family
as a comparison study to see which isoforms are the predominant members of the
family in each tissue. This information would help in understanding the role that the
family has in the human body.

Regulation of CYP4Fs during inflammation
Inflammation is known for its contribution to the host defense mechanism
where it aids in the fight against infection by a variety of pathogens as well as
tissue injury. On the other hand, it also can become diffuse and uncontrolled and
thereby produce unwanted complications. The importance of CYP4Fs are shown
during this process because after a bacterial infection or tissue injury
polymorphonuclear leukocytes (PMNL) or neutrophils are activated and recruited
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to the site of inflammation by mediators such as LTB4 that causes chemotaxis to
the site of injury [39],[40]. The CYP4Fs ability to control the inactivation of LTB4
plays an important role in making sure excess LTB4 is not in the system, which
could lead to unregulated inflammation. Studies examined the changes in CYP4F
expression during an inflammatory response to determine if indeed the CYP4Fs
have a capability to resolve inflammation [41]. Kalsotra et al. hypothesized that
during the pro inflammatory phase of host defense there was a low expression
level of CYP4Fs, which begins to show a marked up-regulation of CYP4Fs as the
anti-inflammatory phase starts. This elevation of CYP4F activity supports the
resolution of the excess of inflammatory mediators [32]. These findings have led
our laboratory to study the functions of the specific CYP4F isoforms that are
expressed in the human, and examine how they are regulated during an
inflammatory response. Our goal is to provide a basis for how these important
enzymes work throughout an inflammatory episode. This understanding may in the
future lead to better drug design for modulating inflammation.

16

Chapter Two: Human Distribution, Expression and
Inflammatory Mediator Regulation of CYP4Fs

17

Abstract
Cytochrome P450s (CYP) play a central role in the the metabolism,
elimination and detoxification of xenobiotics but many of them play a key role in the
metabolism of endogenous compounds. The CYP4F family is instrumental in the
inactivation of leukotriene B4, a potent inflammatory mediator. However, not much
is known about the relative expression of each CYP4F isoform in human tissues. In
this study we determined the expression profiles of the CYP4F isoforms in the liver,
lung, heart, kidney and spleen. We show that during an inflammatory response in
tissue samples the profile of the CYP4F isoforms change and that the changes
seen are consistent with the presence of inflammatory cytokines. Using the HepG2
human liver cell line we determined that IL-1#, TNF! and IL-6 causes a decrease
in CYP4F expression, but that IL-1# and TNF! causes an increase in CYP4F11
expression, which is a different regulatory response from its other family members.
Overall, the study confirms what was shown in animal model studies is also seen
in human tissues and cells.
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Background
Cytochrome P450s (CYP) catalyze lipophilic compounds into compounds
that are more soluble. They play a central role in the metabolism, elimination and
detoxification of xenobiotics. Studies have recently focused on the extra-hepatic
metabolic capacities of these enzymes and shown discrete and different activity
profiles for extra hepatic tissues. There is also evidence that the different tissue
organs regulate extra-hepatic drug metabolizing enzymes in a specific manner that
may be associated with the function of that tissue [9]. Several studies have been
performed in animal models to determine the distribution and expression of
cytochrome P450s [42][43]. However, it is not always possible to translate animal
distribution studies to humans with accuracy and certainty [44]. This lack of close
correlation may be due to the differences in the number of cytochromes P450 and
isoform specificity from one species to another [45].
Our current study focuses on the CYP4F family of enzymes and their
localization and regulation. This CYP4F family was first identified because of the
ability to inactivate leukotriene B4 (LTB4), a powerful mediator of inflammation [28].
Currently seven identified human isoforms in the CYP4F family have been
identified, and in this study we focus on CYP4F2, CYP4F3A, CYP4F3B, CYP4F11
and CYP4F12. These isoforms vary in their substrate specificity. CYP4F2 is known
for its ability to metabolize LTB4 or arachidonic acid (AA) [46]. CYP4F3A and
CYP4F3B are splice variants of each other that are able to metabolize LTB4 and
AA [47]. Christmas et al. were able to show that CYP4F3A has a greater ability of
metabolizing and deactivating LTB4 [47] while CYP4F3B is more efficient at
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metabolizing AA into 20-hydroxyeicosatetraenoic (20-HETE) [48]. CYP4F11, unlike
the other members of the CYP4F family, is efficient at catalyzing xenobiotics with
higher affinity than endogenous compounds like LTB4 and AA [31]. The final
isoform in this study is CYP4F12; it is able to metabolize AA and prostaglandins
(PG), which may also help in the termination of inflammation [36].
To determine the distribution of CYP4F isoforms in human liver, lung,
spleen, heart and kidney, we designed qRT-PCR assays that quantify the mRNA of
each of the CYP4F isoform family members. We also examined the role
inflammatory mediators play in the expression and regulation of the CYP4F
isoforms under in vivo and in vitro conditions.

Materials and Methods
Chemicals
IL-1#, TNF! and IL-6 were obtained from Invitrogen Inc. (Carlsbad, CA).
Human Sample RNA
Pooled Human RNA were purchased from Clontech, Mountain View, CA.
Human tissue samples from the liver, heart, lung, spleen and kidney were also
collected and flash frozen by the Department of Pathology at the University of
Texas Health Science Center Houston from Memorial Hermann Hospital. This was
done in accordance to IRB approval by the University of Texas Health Science
Center Houston. A description of the human samples is presented in Table 2.1.
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Cell Culture
HepG2 cell line was obtained from the American Type Culture Collection
(Manassas, VA). Cells were grown at 37oC in a humidified incubator with 5% CO2
in Minimum Essential Medium (Sigma-Aldrich) supplemented with 10% fetal bovine
serum (Atlas Biologicals, Fort Collins, CO), L-glutamine and Pen/strep antibiotics.
Cytokine treatments were administered 24 hours after seeding the cells and the
cells were treated for 24 hours in each case unless otherwise noted.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Human samples were homogenized in TRIzol reagent (Invitrogen) while
cells were rinsed with phosphate-buffered saline (PBS), and then subjected to
RNA isolation using TRIzol reagent (Invitrogen). DNase I (Invitrogen) was used to
alleviate DNA contamination. Aliquots (100 ng) of total RNA were reversetranscribed by SuperScript II Reverse Transcriptase (Invitrogen) in triplicate,
including a reverse transcription blank to evaluate the presence of contaminating
genomic DNA. Amplification was performed using Taq DNA Polymerase
(Invitrogen) with an ABI Prism 7700 (Applied Biosystems, Foster City, CA) at 95oC
for 1min, followed by 40 cycles at 95oC for 12s and 60oC for 30s. CYP4F mRNA
levels were measured using standard curves generated by plotting Ct versus the
log of the amount of purified amplicon for CYP4F (custom synthesis by Invitrogen)
(200ag - 2pg). Abundance of human 18S RNA was used as an internal control.
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Sample

Clontech!
Clontech!
Clontech!
Clontech!
Clontech!
H673! !
H678! !
H693! !
H696! !
H6103!!

Tissue Type

Li!
!
Lu!
!
K!
!
S!
!
H!
!
Li,Lu,K,S,H!
Li,Lu,K,S,H!
Li,Lu,K,S,H!
Li,Lu,K,S,H!
Li,Lu,K,S,H!

Sex

M!
M/F!
F!
M/F!
M!
F!
M!
M!
F!
F!

Pool Size

Age

Race

C.O.D.

1!
3!
1!
12!
3!
1!
1!
1!
1!
1!

51!
32-61!
40!
18-54!
30-39!
71!
50!
58!
78!
63!

C!
C!
C!
C!
C!
C!
C!
C!
C!
C!

Sudden Death
Sudden Death
Sudden Death
Sudden Death
Trauma
CRF, HTN
Li/K Failure
Septic Shock
Septic Shock
Septic Shock

!
!
!
!
!
!
!
!
!
!

Li=Liver, Lu=Lung, K=Kidney, S=Spleen, H=Heart, M=Male, F=Female, C=Caucasian,
AA=African American,CRF=Cardiorespiratory Failure, HTN=Hypertension

Table 2.1. Total RNA Source Information
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Primers and fluorescent probe sequences for CYP4F isoforms and 18S RNA are
reported in Table 2.2.
Statistical Analysis
Data are presented as mean ± S.E.M. One-way analysis of variance
followed by Dunnett’s multiple comparison test was used for the statistical analysis.
Statistical differences were considered significant if P <0.05.
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Name!
CYP4F2
!
!
!
!

Primers/Probes
!

!

5ʼ-3ʼ Sequence

Forward Primer!
Reverse Primer!
Probe! !
!

CCAGAACAGGCCAATCTGAA
CTCCTCAGTCCCACCTCCC
ATGCATAGCGGATTGGTGGCTTTCA

CYP4F3A!
!
!
!
!

Forward Primer!
Reverse Primer!
Probe! !
!

TCTGGATGGGCCCCATCT
TTGATGACAGACCGGATGATGT
CGTCATCCGTTTTTGCCACCC

CYP4F3B!
!
!
!
!

Forward Primer!
Reverse Primer!
Probe! !
!

GCCCTGGCACGCAATC
GGAGCAAAGAGCACAGGCTT
TCCGCATCTTCCACCCCACCTAC

CYP4F11!
!
!
!
!

Forward Primer!
Reverse Primer!
Probe! !
!

CGAAACAGAACTGGTTTTGGG
GGTCAATGTCTTCATGCCCTC
AGGGCCTGGTCACTCCCACGG

CYP4F12!
!
!
!
!

Forward Primer!
Reverse Primer!
Probe! !
!

ATGTCGGCCACCTATTCCC
AGGGTGGCATAAAACGATGA
TTACGGTATGGCTGGGTCCCATCAT

Human 18S! Forward Primer!
!
!
Reverse Primer!
!
!
Probe! !
!

GAGGGAGCCTGAGAAACGG
GTCGGGAGTGGGTAATTTGC
TACCACATCCAAGGCAGCAGG

Table 2.2. Sequences of oligonucleotides comprising Human
CYP4F isoform TaqMan assays
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Results
CYP4F Isoform expression is varied across human tissue samples
Our laboratory has previously shown that in the rat the expression of CYP4F
isoforms are varied across liver, lung, brain and kidney rat tissues [49]. We
designed this current study to determine the expression profile of the various
CYP4F isoforms across human liver, lung, heart, kidney, spleen and brain tissue.
Liver
The CYP4F2 isoform was the predominant CYP4Fs being expressed in the
human liver with the other isoforms showing minimal expression. The CYP4F
isoform expression level ranking is CYP4F2 > CYP4F3B > CYP4F11 > CYP4F12 >
CYP4F3A as is represented in Figure 2.1.
Lung
In the human lung the CYP4F isoform distribution was as follows:
CYP4F3B> CYP4F12 > CYP4F11 > CYP4F2 > CYP4F3A. CYP4F3B represented
a significant large percentage of the CYP4F expression in the human lung, while
CYP4F3A had only minimal expression levels. Figure 2.1.
Heart
In the heart the distribution of CYP4Fs follows the order of CYP4F3B >
CYP4F12 > CYP4F2 > CYP4F11 ~ CYP4F3A as seen in Figure 2.1
Spleen
The spleen had the following order of expression: CYP4F3B > CYP4F2 >
CYP4F12 > CYP4F11 ~ CYP4F3A. The expression in the spleen shows a
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representation of mostly CYP4F3B with a smaller expression profile for CYP4F2.
There is minimal expression of CYP4F3A, CYP4F11 and CYP4F12.
Kidney
The kidney like the liver was very high in expression of CYP4F2 and
CYP4F3B isoforms. The distribution is as follows: CYP4F2 > CYP4F3B >
CYP4F11 ~ CYP4F12 > CYP4F3A.
The distribution of CYP4F isoforms in various tissues are represented in the
pie chart showing their relative expression (Figure 2.2). This varying degrees of
isoform distribution is consistent with the differences in expression levels observed
in our previous studies of the rat model [49].
Patient samples with diseases that have an inflammatory component have
varied level of CYP4F expression
To determine whether inflammation plays a role in the regulation of CYP4Fs
we examined patient samples with an inflammatory component implicated in the
cause of death. The cause of death was determined by a pathologist using
markers of inflammation in histological slides of each tissue. We were able to
compare the degree of alteration in CYP4F expression profile occurring in each
tissue in comparison to the averaged expression levels for each form in each
tissue. Figure 2.3A shows a representative sample of a patient with a disease with
an inflammatory component and illustrates the changes in the expression profile of
CYP4Fs resulting from inflammation in that tissue. The liver sample from patient
H6103 liver had inflammatory markers based on histological markers seen in the
slide Figure 2.3B. Increased inflammatory markers are identified as an infiltration of

26

neutrophils and leukocytes. As noted in Table 2.1 the cause of death for patient
H6103 was septic shock, which causes the release of a myriad of inflammatory
mediators throughout the body. Further, pathological analysis of the liver resulted
in an inflammatory rating of two and a diagnosis of hepatitis. When examining the
distribution differences between liver sample H6103 and pooled liver we found
significant increase in expression of CYP4F11, CYP4F3B, and CYP4F3A isoforms.
Figure 2.4A also shows a representative sample of a patient with a disease that
included an inflammatory component and the alterations it causes in the
expression profile of CYP4Fs. The liver sample from patient H696 liver had
increased inflammatory markers such as infiltrated neutrophils and leukocytes, as
is seen in Figure 2.4B. As noted in Table 2.1 patient H696 died of septic shock as
well, and the spleen was given an inflammatory rating of two with a reactive
hyperplasia and the presence of hemorrhage and white pulps. When examining
the distribution differences between sample H696 and pooled liver we observed
significant increase in CYP4F11, CYP4F2, and CYP4F3A isoform expression.
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Figure 2.1. Transcript Copy Numbers of CYP4F Isoforms Across
Different Tissues. Total RNA from samples listed in Table 2.1 were
used to asses the mRNA transcript numbers of CYP4F isoforms in
the liver, lung, heart, kidney and spleen. CYP4F2 and CYP4F3B
shows the highest level of transcript copies across most tissues.
CYP4F3A, CYP4F11 have minimal expression across varied tissues
and CYP4F12 showed differences from high in the lung to low out of
most other tissues.
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Figure 2.2 Isoform and Tissue Specific CYP4F Distributions.
Total RNA from samples listed in Table 2.1 were prepared and
assayed using qRT-PCR as described in the Methods and Materials
section. The pie charts represent the relative distribution of CYP4F
isoforms in the liver, lung, kidney, heart and spleen.
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Figure 2.3. Sample 103 Inflamed Liver Compared to Pooled
Liver.
A) Sample 103 inflamed liver that was diagnosed with hepatitis was
used to compare any changes seen in CYP4F isoforms in a
diagnosed inflammatory tissue. There was an increase in CYP4F11,
CYP4F3A, and CYP4F3B while there was a reduction in CYP4F2
expression. B) A representative histological slide of sample 103’s
liver with an increase of infiltrated neutrophils which represents the
presence of inflammation.
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Figure 2.4. Sample 96 Inflamed Spleen Compared to Pooled
Spleen.
A) Sample 96s’ inflamed spleen that was diagnosed with reactive
hyperplasia was used to compare any changes seen in CYP4F
isoforms in a diagnosed inflammatory tissue. There was an increase
in CYP4F11, CYP4F3A, and CYP4F2 while there was a reduction in
CYP4F3B expression. B) A representative histological slide of sample
96s’ spleen with an increase of infiltrated neutrophils which
represents the presence of inflammation.
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Specific cytokines can change CYP4F isoform expression in HepG2 cells
To determine whether if proinflammatory cytokines can regulate the
changes seen in CYP4F isoforms we conducted a 24-hour treatment study on
HepG2 cells with cytokines and measured the levels mRNA transcripts of each
CYP4F isoform. We tested IL-1#, TNF! and IL-6 cytokines and found that in most
cases IL-1# and TNF! caused a down regulation of CYP4F isoforms (CYP4F2,
CYP4F3B, and CYP4F12) while IL-6 seemed to play little to no role in regulating
the CYP4Fs. CYP4F11 however showed an increase in transcript levels in the
presence of both IL-1# and TNF!. The ability to change CYP4F expression profiles
in a controlled environment provides more evidence that indeed the inflammatory
response in human tissues induce changes to these enzymes that metabolize
xenobiotics endogenous compounds.
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Figure 2.5. Cytokine Regulation of CYP4F Isoforms in HepG2
cells.
HepG2 cells were plated then treated for 24 hours with either Vehicle,
IL-1#, TNF! or IL-6 (10ng/ml). Total RNA was collected after the 24
hour time-period and qRT-PCR was used to quantify the specific
isoform expression amount. IL-1# and TNF! were able to change the
expression profiles of CYP4F2, CYP4F3B, CYP4F12 and CYP4F11.
IL-6 did not vary much from control levels.
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Discussion
Phase I metabolizing enzyme research has focused on the liver as the
preferred site of experiments because of its known role as the principle organ of
biotransformation [50]. It is also believed that xenobiotics are mainly metabolized
by cytochrome P450 (CYP)1,2 and 3 family members, and that the other family
members focus mainly on endogenous compound trasformation [8]. There has
been extensive work done on the regulation, expression profile and function of
these family members [43][51-53]. Though much research has focused on the liver
because of its functional role in biotransformation, every major tissue has some
ability to metabolize xenobiotics [50]. Knowing this information is important
because when considering drug disposition the total effect must determined; thus
the additive effect of all tissues is important [54]. Many studies have examined the
expression and localization of members of the CYP family of genes. Five members
of the CYP2C family have been examined by Tsao et al. and they found that there
were varied expression profiles of the genes across the murine model [55]. They
determined that the sites of these enzymes’ expression also play a functional role
in that specific tissue [55]. Ding et al. published a review that examined the CYP1,
2 and 3 families to identify their presence in different parts of the respiratory and
gastrointestinal tracts [56]. Another study determining the expression and
localization of the CYP3A subfamily found that the genes were expressed at
different levels across different tissues and suggested that this was due to tissue
specific regulation of the promoter region [57]. There is a limited amount of
information about the distribution and localization of the CYP4F family in humans.
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We undertook to examine the liver, lung, heart, kidney and spleen of a variety of
human samples and determine the averaged mRNA expression of the CYP4F
isoforms using the highly sensitive technique qRT-PCR. We found that CYP4F2
and CYP4F3B were the most expressed CYP4F isoforms across the different
human tissues. CYP4F2, which is responsible for the inactivation of LTB4 and
metabolizes AA into 20-HETE, was highly expressed in the liver and the kidney. Jin
et al., reported that the Chinese Human Liver Proteome Profiling Consortium had
obtained 42% CYP4F2 and 29% CYP4F3 relative protein abundance in the liver as
compared with CYP3A4 [58]. This finding is consistent with the mRNA levels that
we have seen in the liver, and they are in the correct order of relative abundance. It
is also important to note that the high levels of CYP4F2 and CYP4F3B in the
kidney can produce 20-HETE that helps modulate vascular tone and renal tubular
function [59, 60]. CYP4F3A was the original CYP4F3 found in neutrophils and is
known for its ability to inactivate LTB4, and CYP4F3B was found to be highly
present in liver and kidney using northern blot techniques [48]. We also found that
there was a high level of CYP4F12 transcripts in the heart and lung, and very little
in the other tissues. It has been reported that CYP4F12 protein is expressed in the
liver and kidney in small amounts, but that the highest expression of CYP4F12
protein was in the seminal vesicles and prostate gland [38]. They reported little to
no CYP4F12 protein in the aorta and no information was reported about the lung
[38]. Thus, further studies would have to be performed to see precise localization
of the CYP4F12 protein to determine whether the mRNA expression levels

40

correlate with protein levels. Overall, CYP4F11 showed small amounts of
expression across all the tissues tested.
This study determined the constitutive levels of Human CYP4F isoforms so
that there could be a comparison of what these levels are during an inflammatory
response. Many studies have reported that inflammatory mediators can cause a
change in the expression profile of CYPs [20, 27, 61-63]. The idea that the same
down-regulation that occurs in other CYPs could effect the CYP4F family is mainly
based on animal model studies done in our lab and other laboratories that show
that after injury and the pro-inflammatory stage there is a down-regulation of
CYP4Fs. This down-regulation is then reversed in the pro-inflammatory stage of
healing where there is an increase in CYP4Fs to help in resolving the inflammatory
mediators such as LTB4 [64-67]. To study this we compared known inflamed
tissues defined by histological analysis from patient samples and compared them
to our pooled tissue samples. We found that there is a change in CYP4F
expression profile in the presence of inflammatory mediators. Of importance is the
higher expression of CYP4F3A seen in these samples, which we believe is
correlative to the presence of neutrophils at the site of injury/inflammation.
However, the changes seen in the CYP4Fs maybe based on a number of signaling
processes that need to be studied in a different system, which is why we went to
cell culture to identify signaling pathways for changes we saw in the CYP4F
expression.
During an inflammatory response or injury a number of cytokines are
released as part of the host response [68]. We chose to determine how IL-1#,
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TNF! and IL-6 would effect the expression of the CYP4Fs. We found that for a
majority of the CYP4Fs, IL-1# and TNF! treatment caused down-regulation of
mRNA CYP4F transcripts except for that of CYP4F11. IL-6, however, seems to
have little to no effect on the expression of the CYP4Fs. We also found that there
was no significant difference between cytokine-treated and control CYP4F3A
expression. The conclusion that CYP4F11 can be up-regulated during an
inflammatory response and its ability to metabolize xenobiotics could potentially be
beneficial to pharmaceutical companies looking for a way to control unwanted
inflammatory mediators in tissues. Understanding more about the regulatory
controls of the CYP4F family and their ability to resolve inflammation, although still
in its infancy stage, could become a major help in treating patients.
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Chapter Three: Isoform, Ethnicity and Sex Specific
Expression Differences in Human Orbital Frontal
Cortex

43

Abstract
!
Cytochrome P450s play an important role in the brain. They are responsible
for metabolism of neurosteroids, neurotransmitters,and xenobiotics in the brain.
This study determined the expression of the isoforms of CYP4F family of enzyme
in the orbital frontal cortex. We found that CYP4F11, an enzyme that metabolizes
xenobiotic and endogenous compounds was expressed at a significantly higher
quantity than its other family members. Immuno-histochemical studies revealed
that the CYP4F11 protein is localized in neuron and glial cells and that expression
of CYP4F11 is not ubiquitous across all cells. We also found that while gender
does not affect the CYP4F isoform expression in the orbital frontal cortex, ethnicity
does. African Americans express CYP4F11 at a significantly higher rate than their
Caucasian counterparts. Overall, this study is the first demonstration of the
importance of CYP4F11 expression in brain.
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Background
!

Extensive work has been done on the metabolism of xenobiotics in the liver

and extra-hepatic tissues. This is because xenobiotics are found in all facets of our
environment, they range from the drugs we take to the air we breath to the food we
eat. Cytochrome P450s (CYP) have been identified as the key enzyme that starts
the detoxification process for these compounds by transforming them from
lipophilic to more polar hydrophilic metabolites. Because xenobiotics come in a
variety of shapes and sizes, the CYP enzymes have been located in all tissues and
consist of a diverse number of enzymes within its superfamily. Although there has
been extensive research on the CYP expression in the liver and other extrahepatic tissues the brain has special properties that make it unique. One of the
main characteristics that is unique to the brain is the presence of the blood brain
barrier (BBB). The BBB is made up of 3 cellular components: endothelial cells,
astrocyte feet and pericytes [69]. The BBB is further characterized by the presence
of tight junctions which help create a selective barrier to prevent the transport of
hydrophilic molecules across the BBB; however, small lipophilic compounds and
molecules can cross the barrier [69]. The astrocyte end feet that cover 90% of the
endothelial cell surface can also release chemical factors and signals that can
regulate the permeability of the endothelium [70]. The brainʼs limited ability to
regenerate and the lipophilic characteristics of xenobiotics leaves the brain
vulnerable to damage by toxic compounds. Thus the presence of CYPs to
metabolize any lipophilic compound that enters the brain is of great importance in
detoxification and therefore protection of the brain.
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!

Many of the CYP family members have been identified in the brain, and they

include CYP subfamilies 1, 2, 3 and 4 [71]. What many researchers have found is
that the expression levels of CYPs in the brain are about 1-10% of that in the liver
[72, 73]. Although there is less representation of CYPs in the brain, the expression
of most are in specific regions of the brain, and some members of the CYP family
of enzymes also show specific splice variants in the brain.
!

Although CYPs play a role in catalyzing the detoxification of xenobiotics

crossing the BBB, a greater majority of CYPs in the brain specialize in the
formation of biologically important lipid signaling molecules such as eicosanoids
and steroid hormones. These molecules include: estrogen, corticosteroids, bile
acids, vitamin D, and androgens [74]. Another important function of CYPs in the
brain is the synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) from
aracidonic acid (AA). This activity is important because 20-HETE plays a role in
regulating cerebral blood flow and helps in the vasodilation actions of nitric oxide in
cerebral circulation [75]. Studying CYP4F expression in the brain is of great
importance because of this last point. Many of the isoforms in the CYP4F family
metabolize AA into 20-HETE and to know their expression patterns in the brain
helps us understand more about how the brain is functioning. This current study
was planned to identify which CYP4F isoforms are expressed in the brain and
identify cell types, whether it be neuronal or glial, that express the CYP4Fs.
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Materials and Methods
Human Sample RNA
Brain samples were collected from the National Institutes of Health by Dr.
Thomas Hyde in accordance to NIH IRB approval of human samples. All samples
were from the orbital frontal cortex, and sample descriptions are listed in Table 3.1.
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Human samples were homogenized in TRIzol reagent (Invitrogen) while
cells were rinsed with phosphate-buffered saline (PBS), then subject to RNA
isolation using TRIzol reagent (Invitrogen). DNase I (Invitrogen) was used to
alleviate DNA contamination. Aliquots (100 ng) of total RNA were reversetranscribed with SuperScript II Reverse Transcriptase (Invitrogen) in triplicate,
including a reverse transcription blank to evaluate presence of contaminating
genomic DNA. Amplification was performed using Taq DNA Polymerase
(Invitrogen) with an ABI Prism 7700 (Applied Biosystems, Foster City, CA) at 95oC
for 1min, followed by 40 cycles at 95oC for 12s and 60oC for 30s. CYP4F mRNA
levels were measured using standard curves generated by plotting Ct versus the
log of the amount of purified amplicon for CYP4F (custom synthesis by Invitrogen)
(200ag - 2pg). Abundance of human 18S RNA was used as an internal control.
Primers and fluorescent probe sequences for CYP4F isoforms and 18S RNA are
reported in Table 3.2.
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Sample
910
922
942
1007
1051
1053
1054
1056
1099
1109
1127
1275
1276
1314
1443
1458
1473
1522
1525

BrainRegion
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex
Orbital Frontal Cortex

AGE (yr)

Gender
52
51
61
57
57
40
58
48
67
59
43
60
24
53
56
34
44
64
46

F
M
M
M
F
F
M
M
F
F
F
M
M
F
M
M
M
F
M

Ethnicity
AfAm
Cauc
Cauc
AfAm
AfAm
AfAm
AfAm
AfAm
AfAm
Cauc
AfAm
AfAm
AfAm
AfAm
Cauc
Cauc
AfAm
AfAm
AfAm

PMI (hr)
10
30.5
19.5
25
19
25
28.5
37
34
23
72
13
43.5
50.5
29.5
13.5
29
52.5
13

F=Female, M=Male, AfAm=African American, Cauc=Caucasian, PMI=Post-Mortem Interval

Table 3.1. Total Brain RNA Characteristic Information

48

Name!
CYP4F2
!
!
!
!

Primers/Probes
!

!

5ʼ-3ʼ Sequence

Forward Primer!
Reverse Primer!
Probe! !
!

CCAGAACAGGCCAATCTGAA
CTCCTCAGTCCCACCTCCC
ATGCATAGCGGATTGGTGGCTTTCA

CYP4F3A!
!
!
!
!

Forward Primer!
Reverse Primer!
Probe! !
!

TCTGGATGGGCCCCATCT
TTGATGACAGACCGGATGATGT
CGTCATCCGTTTTTGCCACCC

CYP4F3B!
!
!
!
!

Forward Primer!
Reverse Primer!
Probe! !
!

GCCCTGGCACGCAATC
GGAGCAAAGAGCACAGGCTT
TCCGCATCTTCCACCCCACCTAC

CYP4F11!
!
!
!
!

Forward Primer!
Reverse Primer!
Probe! !
!

CGAAACAGAACTGGTTTTGGG
GGTCAATGTCTTCATGCCCTC
AGGGCCTGGTCACTCCCACGG

CYP4F12!
!
!
!
!

Forward Primer!
Reverse Primer!
Probe! !
!

ATGTCGGCCACCTATTCCC
AGGGTGGCATAAAACGATGA
TTACGGTATGGCTGGGTCCCATCAT

Human 18S! Forward Primer!
!
!
Reverse Primer!
!
!
Probe! !
!

GAGGGAGCCTGAGAAACGG
GTCGGGAGTGGGTAATTTGC
TACCACATCCAAGGCAGCAGG

Table 3.2. Sequences of oligonucleotides comprising Human
CYP4F isoform TaqMan assays
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Immunohistochemical Analysis
!

Tissue fixation and immunohistochemistry solvents were all certified

histological grade and obtained from Fisher Scientific (Pittsburgh, PA). Brain
samples were fixed in 10% formalin solution, after surgical extraction by our
neuropathologist colleague from Memorial Herman Hospital. Samples were then
fixed being dehydrated in a series of ethanol (50%, 70%, 95%, 100%) and xylene
solutions (100%), then embedded in paraffin wax. The wax block molds of brain
tissue were then sectioned and mounted onto poly-L-lysine coated glass slides.
For immunohistochemical analysis, the slides were rehydrated and then taken
through an antigen retrieval process. The tissue samples were incubated at 4oC
overnight in primary antibody solution, then incubated for at least 1 hour in
secondary antibody solution. The primary antibody solution contained antibody to
CYP4F11 (1:100) and antibody to either MAP2 (1:500), or GFAP (1:1000). The
secondary antibody solution was either AlexaFluor-594 anti-rabbit (1:250) or
AlexaFluor-488 anti-mouse (1:250). The slides were also treated with ProLong
Gold Antifade Reagent that contained DAPI to stain for cell nuclei. The slides were
then visualized on a fluorescence microscope and images were captured using
SPOT RT Slider imaging system. The background color of the microscope images
was adjusted using Adobe Photoshop.
Statistical Analysis
Data are presented as mean ± S.E.M. One-way analysis of variance
followed by Dunnett’s multiple comparison test was used for the statistical analysis.
Statistical differences were considered significant if P <0.05.
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Results
Cytochrome P450 4F11 is expressed highly in the Orbital Frontal Cortex.
!

To understand the expression levels of the CYP4Fs in the orbital frontal

cortex of the human brain we performed qRT-PCR using specific primer and probe
sets that distinguish between each isoform in the CYP4F family. 100ng of RNA
from each sample was analyzed and plotted in Figure 3.1. We found that CYP4F11
is the most highly expressed CYP4F isoform in the orbital frontal cortex. There was
little to no expression of CYP4F2 and CYP4F3B in the brain samples. CYP4F3A
was the next most abundant isoform expressed followed by CYP4F12.
Numerically, CYP4F11 represented 88% of the CYP4F family presence in the
orbital frontal cortex and had 20000-25000 transcripts per 100ng of RNA. The
order of relative abundance is described as CYP4F11 > CYP4F3A > CYP4F12 >
CYP4F3B ~ CYP4F2
Gender does not affect CYP4F expression in brain
!

Studies have shown that gender can be a factor in the expression of CYP

enzymes [76, 77]. To elucidate whether gender plays a role in CYP4F expression
in brain, the data obtained from male (n=11) and female (n=8) samples was
compared and demonstrated that gender does not play a significant role in the
expression of CYP4Fs in the orbital frontal cortex (Figure 3.2).
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Figure 3.1. CYP4F Isoform Transcript Copy Numbers In Human
Brain. A) Total RNA from samples listed in Table 3.1 were used to
asses the mRNA transcript numbers of CYP4F isoforms in the brain.
B) CYP4F11 shows the highest level of transcript copies compared to
other CYP4F’s.
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Figure 3.2 Gender differences of CYP4F expression are not
observed In orbital frontal cortex.
qRT-PCR was used to obtain transcript copy numbers for each
CYP4F isoform and compared between male and female samples to
determine if gender has an affect on CYP4F expression in the brain.
We determined that there were no significant gender differences
seen in any CYP4F isoform’s expression in the brain.
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CYP4F11 expression is more abundant in African Americans compared to
Caucasians
!

There is growing evidence that ethnicity may play a role in the expression of

CYP enzymes [78-81]. To determine if ethnicity was a factor in the expression of
the CYP4F family of enzymes we analyzed the expression of each isoform in the
orbital frontal cortex of each of our samples. We then compared the African
American samples (n=14) to the Caucasian samples (n=5) for each isoform and
determined differences if any in the expression of the enzyme (Figure 3.3). We
found that CYP4F11 is expressed in high quantities in the African American
population as compared to the Caucasian population. CYP4F2 on the other hand
showed a greater presence in the Caucasian population as compared to the
African American population where the expression of CYP4F2 was either low or
absent in the sample population. However, due to the variance in the Caucasian
population this finding was not significant at the P<0.05 level. This trend was also
seen in the expression of CYP4F3B and CYP4F12. CYP4F3A, however, showed
few differences in expression between the two ethnic populations.
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Figure 3.3 Ethnicity Differences of CYP4F Isoforms In Human
Brain.
qRT-PCR transcript copy number comparison between African
American and Caucasian samples to determine if ethnicity has an
affect on CYP4F expression in the brain. CYP4F11 expression in
African Americans is significantly higher than in their Caucasian
counterparts. CYP4F2, CYP4F3B and CYP4F12 showed higher
expression in Caucasian samples, but it was not statistically
significant at the P<0.05 level. There also was no difference in
CYP4F3A expression between the two ethnicities.

55

***

56

Cytochrome P450 4F11 is expressed selectively in both glial and neuronal
cells
!

Immunofluorescent techniques were used to determine the expression of

the protein in human brain samples. We used microtubule-associated protein 2
(MAP-2) to stain for neuronal cells, and glial fibrillary acidic protein (GFAP) to stain
for glial cells, specifically astrocytes, in the brain (Figure 3.4 and Figure 3.5).
CYP4F11 is being expressed in both glial and neuronal cells, but in specific cell
types of each. The merged picture shows the overlap of CYP4F11 and either
MAP-2 or GFAP. It also appears that the CYP4F11 is not present in the nuclei of
these cells.
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Figure 3.4. Localization of CYP4F11 Protein In Human Brain Glial
Cells.
A) Immuno-fluorescent slide of human brain, DAPI staining of nuclei.
B) GFAP (1:1000) in green staining glial cells C) CYP4F11 (1:100) in
red. D) Merged picture showing overlap of GFAP and CYP4F11.
There are also areas of no overlap representing CYP4F11 being
expressed in other cells
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A.

B.

Figure 3.5. Localization of CYP4F11 Protein In Human Brain.
A) Immuno-fluorescent slide of human brain. CYP4F11 (1:100) in red
and GFAP (1:1000) in green with DAPI staining of nuclei. Highlighted
area shows that there is overlap of CYP4F11 and Glial Cells B)
CYP4F11 (1:100) in red and MAP2 (1:1000) in green with DAPI
staining of nuclei. Highlighted area shows that there is overlap of
CYP4F11 and Neurons.
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Discussion
!

Currently many cytochrome identification studies in the brain have shown

the expression of the Cytochrome P450 families 1,2 and 3 in the brain [82-84].
However, recently there have been significant strides in identifying CYP4F
expression in the brains of animals. These papers have focused on the importance
of the endogenous compound metabolism and the pathways by which CYP4F
metabolites may have on regulatory functions. There have been a few studies that
identify human CYP4Fs in brain, but none that have taken a comprehensive look at
the human CYP4F family expression [85-87]. In the current study we were able to
show that the expression of CYP4Fs in the human orbital frontal cortex is
dominated by CYP4F11. This finding is surprising because many CYP4Fs that are
expressed in small quantities in the brain are expressed in large quantities in other
tissues, as shown in Chapter 2 of this dissertation. However, what was not
surprising was finding expression of CYP4F11. CYP4F11 was first identified and
cloned from brain tissue and identified in other tissues as well, so its presence was
expected [35]. The presence of a strong CYP4F11 expression provides further
evidence that the brain may have evolved to express specific isoforms to perform
multiple tasks. Kalsotra et al., reported that CYP4F11 was able to metabolize a
great variety of pharmaceutical drugs including erythromycin, benzphetamine,
imipramine and verapamil with acceptable turn-over rates [88]. However, the
authors also show that although the turn-over rate for endogenous compounds
such as leukotriene B4 (LTB4) is not as high as those of other CYP4F isoform
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family members, CYP4F11 is still able to metabolize this compound and others
such as the conversion of arachidonic acid (AA) to 20-HETE [88].
!

The presence of high CYP4F11 mRNA concentration in brain led us to

investigate the localization of CYP4F11 protein in the brain. We found that
CYP4F11 protein is located in both neuronal and glial cells. Since CYP4F11 is able
to metabolize both endogenous compounds like AA and xenobiotics such as drugs,
we believe this dual cell type expression is beneficial for the brain functions of
signaling and detoxification. A majority of CYP enzymes have been reported to
localize to neuronal cells [89, 90]. The localization of CYP4F11 in neuronal cells
could prove to be important because the site of action for psychoactive drugs is in
the neurons [91].
!

When determining the expression levels of each CYP4F isoform we found

little to no expression of CYP4F2 and CYP4F3B in the brain, and as mentioned
earlier in this dissertation these two enzymes metabolize AA into 20-HETE. As
mentioned in the introduction of this chapter, 20-HETE is important in the
neurovascular system of the brain and production of this compound would have to
happen in the cells closest to the site of blood flow, such as the glial cells. The
presence of CYP4F11 in the glial cells and the virtual absence of expression of
CYP4F3B and CYP4F2 suggests a prominent physiological role for CYP4F11 in
brain may be the conversion of AA into 20-HETE. Metea et al., were able to show
that when the CYP4F ω-hydroxylation of AA is inhibited with HET0016 in glial cells,
vasoconstriction is blocked [92].
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!

We found that the expression of CYP4F11 protein may not be present in all

neuronal and glial cells. Dutheil et al., recently published a review which reported
when CYPs are expressed in the brain they are usually seen in specific cell types
and are not ubiquitously expressed throughout brain regions [71]. Further research
needs to be conducted with samples from a larger set of brain regions to define
specific markers for the many different types of neuronal and glial cells in the brain.
!

This current study also shows that gender plays no obvious role in the

expression of CYP4F isoforms in the orbital frontal cortex. There have been many
reports that provide evidence that gender can affect the expression of CYPs.
Waxman et al., recently published a review of CYP families 1,2 and 3 showing how
sex differences cause changes in expression of the CYPs [77]. In the future, with
additional brain regions and larger sample sizes, a significant differences in
expression between genders may emerge, but our study did not find any.
!

We did find that ethnicity-based differences in expression does occur

between African Americans and Caucasians. Our data shows that African
Americans express CYP4F11 at a significantly higher rate than Caucasians. The
Ravindranath laboratory also found that in the Indian population CYP4F11 was
expressed at a much higher level compared to the other CYP4F family members
(personal communication). A large number of our sample group consisted of
African American samples, so the addition of more Caucasian samples would help
in identifying whether CYP4F11 can be expressed in a high quantity in this group.
We examined the promoter region of CYP4F11 for single nucleotide
polymorphisms (SNPs) Figure 3.6. Using HapMap (www.hapmap.org), we found

63

that a SNP labeled rs3810427(C/A) occurs at a rate of .868/.132 in African
Americans while it is .496/.504 for most Caucasians while the other SNPs in Figure
3.6 were equal in both ethnicities. This means that the C nucleotide occurs 87% of
the time in African Americans while in Caucasians this occurrence is only 50%. The
SNP in this region could be in a critical promoter region binding site, or there also
could be other SNPs in the gene that could be causing the difference in
expression. This work is a preliminary attempt to understand the differences
between the two ethnicities in CYP4F11 expression. Additional work is needed in
this area to more fully understand any differences in expression. Other studies
have also determined that ethnic differences play a role in the expression and
function of many CYPs. Yamaori et al., for instance, reported that there was a
difference in expression of CYP3A5 between Japanese and Caucasian subjects
[81].
!

Our CYP4F expression work in human brain is a beginning for additional

studies of CYP4Fs in the brain. As more work is done to identify the expression,
localization and functional capabilities of CYPs in the brain is accomplished, there
is a higher probability of identifying potential brain drug target opportunities and
perhaps useful therapies.
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Figure 3.6. 1.7kb 5ʻUTR of CYP4F11. The promoter region is
marked with annotation of SNPs that occur in the population. SNPs
were located using HapMap, www.hapmap.org. and sequence was
analyzed using Geneious (BioMatters)
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Chapter Four: Regulation of Cytochrome P450
4F11 by Nuclear Transcription Factor-Kappa B
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Abstract
The mechanisms that regulate CYP4F genes are currently being studied in
a number of laboratories, but the specific mechanisms for the regulation of these
genes are not yet fully understood. This study shows that nuclear factor kappalight-chain-enhancer of activated B cells (NF-"B) can inhibit CYP4F11 expression
in human liver carcinoma cell line (HepG2). Tumor necrosis factor-! (TNF-!), a
proinflammatory cytokine has been shown to activate NF-"B signaling while also
making active the c-Jun N-terminal Kinases (JNK) signaling pathway. Previous
studies have reported that JNK signaling can up-regulate CYP4F11 expression,
and in this study we have determined that in the presence of TNF-! and the
specific NF-"B translocation inhibitor IMD-0354 there is a greater increase in
CYP4F11 expression, indicating that NF-"B may be playing an inhibitory role.
Furthermore, NF-"B stimulation by over-expression of Mitogen-activated protein/
ERK Kinase Kinase (MEKK) inhibited CYP4F11 promoter expression. We were
also able to rescue CYP4F11 promoter inhibition in the presence of TNF-! when
p65, a NF-"B protein, was knocked down. Thus, the CYP4F11 gene is negatively
regulated by NF-"B signaling pathways.
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Background
The release of several cytokines including tumor necrosis factor (TNF)-!,
interleukin (IL)-1, IL-1b, and IL-6 from activated immune cells in patients with a
disease with an inflammatory component, or infection occur as part of the
activation of systemic host defense mechanisms. This defense mechanism and the
release of these cytokines usually results in the down-regulation of many isoforms
of cytochrome P450 (CYP) [93-98]. This is important due to the known
responsibilities of the CYP systems in the metabolism of drugs used in treatment of
such conditions as well as steroids, lipid soluble vitamins, prostaglandins,
leukotrienes. If there is a disruption in the balance of these enzymes to metabolize
their substrates there could be an alteration in the production or elimination of
these substances and an interruption in the balance between the detoxification and
metabolic bioactivation in the body.
One of the prominent cytokines, TNF-!, is known to be released during
many types of infections and inflammatory diseases [95], and in our current study
we used this cytokine to define the effects its presence has on the regulation of
cytochrome P450 4F11, an isoform of the 4F family that has a substrate profile that
includes not only endogenous compounds but also xenobiotics specifically drugs
[88]. TNF-! stimulation causes an activation of two signal transduction pathways
the c-Jun N-terminal Kinases (JNK) and nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-"B) pathways [99-101]. Our previous studies have
examined the role JNK and retinoic acids play in the regulation of CYP4F11 and
have found that JNK stimulation causes an increase in CYP4F11 mRNA while
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retinoids cause down-regulation of CYP4F11 mRNA [102]. However, we did not
examine the effects of NF-"B on CYP4F11 expression during TNF-! stimulation.
To understand at a deeper level the regulation of CYP4F11 expression
during inflammation we show in this study that TNF-! and MEKK over-expression
can down-regulate CYP4F11 expression in NF-"B dependent manner. Our results
suggest that there is an intricate regulatory system for control of expression of
CYP4F11 during conditions wherein inflammatory modulators are released.

Materials and Methods
Chemicals
N-[3,5-Bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (IMD-0354)
was obtained from Sigma-Aldrich (St. Louis, MO). TNF! was a gift from Dr.
Jianping Jin (University of Texas-Houston). IL-1 were bought from Invitrogen Inc.
(Carlsbad, CA). Polyclonal anti-CYP4F11 antibody was provided by Proteintech
Group, Inc. (Chicago, IL). Rel B and p65 antibodies were bought from Cell
Signaling (Danvers, MA).
Cell Culture
HepG2 cell line was obtained from American Type Culture Collection
(Manassas, VA). Cells were grown at 37oC in a humidified incubator with 5% CO2
in Minimum Essential Medium (Sigma-Aldrich) supplemented with 10% fetal bovine
serum (Atlas Biologicals, Fort Collins, CO), L-glutamine and Pen/strep antibiotics.
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Protein Isolation and Western Blot Analyses
Protein isolation and western blot analyses for cells in culture were
accomplished using the protocol reported by Wang et al., 2010 [102]. Briefly, Cells
were washed two times with ice cold phosphate-buffered saline and then quickly
detached by gently scraping the plate. Collected cells were spun down at 4500rpm
for 2min at 4oC, in a microcentrifudge and stored at -80oC. Lysates were then
prepared using 50mM Tris-HCl buffer, pH6.8, with 2% SDS. Cell pellets were
dissolved in the lysate buffer then boiled at 95oC for 5 minutes. The cell lysate was
then cleared by centrifugation at 13,000 rpm for 5 minutes in a microcentrifudge.
Protein concentrations of the clear supernatant fraction were measured using the
bicinchoninic acid assay kit (Pierece, Rockford, IL) and subjected to Western blot
analysis.
Protein samples were boiled in Laemmli buffer and resolved
electrophoretically on 4 - 20% gradient Tris-glycine-SDS-polyacrylamide gels (BioRad Laboratories, Hercules, CA). Proteins were transferred to polyvinylidene
fluoride membranes (wet transfer apparatus; Bio-Rad Laboratories). Membranes
were blocked with 5% dried non-fat milk in Tris Buffer with .05% Tween for 1 hour.
Membranes were incubated overnight with antibodies raised against CYP4F11
(1:1000 dilution), Rel B (1:1000), p65 (1:1000), or GAPDH (1:10,000). The
membrane was then washed and incubated at room temperature with horseradish
peroxidase-conjugated secondary antibody (1:2000 dilution) for 1 hour.
Immunoreactivty was visualized using a horseradish peroxidase
chemiluminescense system (Pierce).
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Quantitative Real-Time Polymerase Chain Reaction
Cells were rinsed with phosphate-buffered saline (PBS), and total RNA was
isolated using TRIzol reagent (Invitrogen). DNase I (Invitrogen) was used to
alleviate DNA contamination. Aliquots (100 ng) of total RNA were reversetranscribed by SuperScript II Reverse Transcriptase (Invitrogen) in triplicate,
including a reverse transcription blank to evaluate presence of contaminating
genomic DNA. Amplification was performed using Taq DNA Polymerase
(Invitrogen) with an ABI Prism 7700 (Applied Biosystems, Foster City, CA) at 95oC
for 1min, followed by 40 cycles at 95oC for 12s and 60oC for 30s. CYP4F11 mRNA
levels were measured using standard curves generated by plotting Ct versus the
log of the amount of purified amplicon for CYP4F11 (custom synthesis by
Invitrogen) (200ag - 2pg). Abundance of human 18S RNA was used as an internal
control. Primers and fluorescent probe sequences for CYP4F11 and 18S RNA are
reported in Table 4.1.
Plasmids
pGL3-CYP4F11 plasmid mutants were constructed using human genomic
DNA as a template for PCR. The primer pairs for each mutant are listed in Table
5.2. The products were all 3’ promoter regions of the CYP4F11 (GenBank
accession no. NG_0008335). The PCR products were then cloned into HindIII- and
NheI- digested linear pGL3 Basic lucifearse vector (Promega, Madison, WI) using
the infusion Advantage PCR Cloning Kit (Clontech, Mountain View, CA).
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Transfection and Luciferase Assays
Cells were transfected using Fugene HD Reagent (Roche, Indianapolis, IN)
according to the manufacturer’s protocol. Cells were seeded onto 24 well plates (5
x 104 cells/well). 24 hours after seeding, cells were transfected at a recommended
Reagent:DNA ratio of 4.5:1 with 0.5 µg DNA/well including .03 µg of phRL-SV40
(Promega). Total amount of DNA was maintained at a constant concentration by
adding empty pcDNA3 vector when appropriate. After 24 h of transfection, TNF-!
(10 ng/ml) or IMD-0354 (1 ng/ml) treatment was given for 24 h.
RNAi
Double-stranded, siRNAs targeting p65 were designed and synthesized by
Sigma-Aldrich (St. Louis, MO) 5‘GACAUUGAGGUGUAUUUCA3’,
5‘UGAAAUACACCUCAAUGUC3’, and reverse transfected into HepG2 cells using
Lipofectamine RNAiMAX (Invitrogen). In short, 24 well plates were seeded (5 x 104
cells/well) in the presence of 6 (pmol) and 1µl of Lipofectamine RNAiMAX in 100µl
of Opti-Mem I Serum (Invitrogen). Total media volume was 600µl for a final RNAi
duplex concentration of 10 nM.
Chromatin immunoprecipitation (ChIP) analysis
Binding of p65 transcription factor to the human CYP4F11 promoter region
was determined by ChIP assay according to manufacturer’s protocol (Active Motif,
Carlsbad, CA). HepG2 cells after either 1 or 24 h treatment with TNF-! (10ng/ml)
were fixed using 1% formaldehyde in modified Eagle’s medium for 10 min at 37oC.
The cells were then washed 1x in cold PBS, then treated with 125 mM glycine to
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terminate the cross-linking reaction. The cells were washed again with ice cold
PBS, and collected in PBS containing 1mM phenylmethylsulfonyl fluoride and
Protease Inhibitor Cocktail (Active Motif, Carlsbad, CA). The cells were lysed and
sonicated to shear chromatin. 15 µg of chromatin was then incubated overnight at
4oC with antibody directed against p65. PCR was used to amplify the 222bp region
upstream of the start site of CYP4F11 from the purified DNA-protein immune
complexes. PCR products were run on 2% agarose gel and visualized after
ethidum bromide staining. Controls for the assay were performed using IgG and
input template DNA.
Statistical Analysis
Data are presented as mean ± S.E.M. One-way analysis of variance
followed by Dunnett’s multiple comparison test was used for the statistical analysis.
Statistical differences were considered significant if P <0.05.
Database Sequence Analysis
The TRANSFAC database (BIOBASE, Beverly, MA) was searched using
AliBaba 2.1 (BIOBASE) for putative NF"-B binding sites on the 5’ flanking
sequence (2000 base pairs from the ATG start codon) of CYP4F11 gene.
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Results
NF-!B inhibition increases expression of CYP4F11
Our lab recently published that CYP4F11 expression is increased upon
stimulation with TNF-! in Keratinocyte HaCaT cells [102]. TNF-! activates two
pathways, one being the JNK pathway which we have reported can up-regulate
CYP4F11 through AP-1 binding site, and the NF-"B signaling pathway. It was our
intention to understand what role this transcription factor played in regulation of
CYP4F11. We first determined that 24-hour treatment of TNF-! (10ng/ml) caused
an up-regulation of CYP4F11 mRNA in HepG2 cells measured by quantitative realtime polymerase chain reaction (qRT-PCR). To understand the role NF-"B may
have on the expression of CYP4F11, we inhibited the ability of NF-"B to
translocate to the nucleus from the cytoplasm using the chemical inhibitor
IMD-0354 (1ng/ml). HepG2 cells were co-treated with both the inhibitor and TNF-!
(10ng/ml) (Figure 4.1). There was a significant increase in the expression of
CYP4F11 transcripts as compared to control vehicle. Realizing that NF-"B played
a role in CYP4F11 expression after observing an up-regulation of the gene when
translocation of NF-"B to the nucleus was inhibited, we looked 2000bp upstream of
the start site of the gene in TRANSFAC database using the program AliBaba 2.1
for predictions of transcription factor binding sites (Figure 4.2). The website
predicted 5 different NF-"B binding sites in the promoter region of CYP4F11.
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Figure 4.1. NF-!B inhibition increases expression of
CYP4F11. Up-regulation of CYP4F11 transcripts by
inhibition of NF-"B. HepG2 cells were treated with
10ng/ml of TNF + or - IMD-0354 (1ng/ml) NF-"B
inhibitor for 24 hours. Cells treated with 0.1% DMSO
were used as the vehicle control. Expression of
CYP4F11 was quantitated by qRT-PCR. Each data
point represents n=6
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Figure 4.2. NF-κB binding site predictions.
2000bp upstream of ATG start site for
CYP4F11, predictions calculated through
AliBaba 2.1.

CYP4F11 promoter activity is downregulated after HepG2 activation by TNF-"
and MEKK overexpression.
To determine the TNF-! regulatory region in the CYP4F11 promoter, we
cloned the 1.7kb region upstream of CYP4F11 exon-2 transcription initiation site
into pGL3 basic luciferase vector. We first determined the basal promoter activity,
then activity after treatment with TNF-! and MEKK overexpression in HepG2 cells.
As seen in Figure 4.3A, MEKK and TNF-! treatment of the transfected cells
resulted in a 70-75% reduction in CYP4F11 promoter activity. TNF-! and MEKK
treatment up-regulated control NF-"B luciferase reporter vector activity (Figure
4.3B) but had no effect on pGL3 basic luciferase control vectors Figure 5.C. This
suggests that even though TNF-! causes an overall up-regulation of CYP4F11
transcripts as seen previously in Figure 4.1, the promoter inhibition is
accomplished through NF-"B activation. These data are confirmed through the
over-expression of MEKK which causes a constitutively active NF-"B protein that
also down-regulates CYP4F11 promoter activity.
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Figure 4.3. TNF-" and MEKK suppresses CYP4F11
promoter activity. HepG2 cells were transfected with
1.7kb CYP4F11 promoter-pGL3 basic luciferase (A) or
NF-"B luciferase (B) or pGL3-basic luciferase (C)
reporter vector. 24 hours post-transfection, the cells
were treated with TNF-! (10 ng/ml) for 24 hours and
luciferase activity was measured. Measuring Renilla
luciferase activity of co-transfected phRL-SV40
normalized the transfection efficiencies.
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NF-!B responsive region is present in the first 200bp of CYP4F11 promoter
The prediction of five NF-"B binding sites by AliBaba 2.1 enabled us to
create three deletion mutants to determine the functional importance of these
predicted binding sites (Figure 4.4A) Each construct deletes a predicted NF-"B
binding site. The last 1.5kb mutant construct deleted 3 predicted NF-"B binding
sites that were within 100bp of each other. HepG2 cells were transiently
transfected with all the 5’ deletion constructs with or without MEKK expression
plasmid and treated with or without TNF-!. All the 5’-deletion constructs of the
CYP4F11 promoter were down regulated by TNF-! and MEKK except the 1.5kb bp
CYP4F11 promoter (Figure 4.4B). This result suggests that the NF-"B responsive
region should be within the first 200bp of CYP4F11 promoter. A chromatin
immunopercipitation assay was run on the first 222bp of CYP4F11 promoter region
to see whether the p65 transcription factor was binding to the promoter region to
cause an inhibition of the promoter. Figure 4.5 shows that the protein does bind to
the region, and the relative amount of protein binding the region is TNF-! activation
time-dependent. The time-dependency of activation of NF-"B and JNK have been
reported by many labs [101, 103].
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Figure 4.4. NF-!B responsive region present in the first 200bp of
CYP4F11 promoter. (A) Deletion constructs of CYP4F11 promoter
(B) HepG2 cells were transiently co-transfected with 4 different 5’deletion constructs of CYP4F11 promoter luciferase reporter with or
without MEKK-pcDNA3 and phRL-SV40 to normalize the transfection
efficiencies. TNF-! (10 ng/ml) treatment was initiated 24 hours posttransfection for 24 hours. Luciferase activity was measured 48 hours
after transfection.
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Figure 4.5. NF-!B binds to first 200bp region of CYP4F11
promoter. ChIP assays performed in HepG2 cells that had been
treated with TNF-! (10 ng/ml) or vehicle control for 1 hour and 24
hours. The pull down of p65 is seen in the 200bp amplicon region in
both 1 and 24 hours.
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NF-!B is required for CYP4F11 down-regulation
The next goal was to determine the importance of NF-"B in the downregulation of CYP4F11 in response to TNF-!. We achieved this by using the IKK!
phosphorylation inhibitor IMD-0354. This drug inhibits the translocation of NF-"B to
the nucleus, thus preventing any regulatory controls NF-"B exerts on its response
genes. HepG2 cells were transiently transfected with each CYP4F11 deletion
luciferase promoter construct, then co-treated with TNF-! (10 ng/ml and IMD-0354
(1 ng/ml). As shown in Figure 4.6, CYP4F11 promoter activity is not downregulated by TNF-! in the presence of IMD-0354. To make sure there were no drug
interactions that were affecting the results, the experiment was repeated in HepG2
cells in the presence of siRNA that knocks down p65 thus preventing expression.
Figure 4.7 shows that after p65 knockdown and in the presence of TNF-! or overexpression of MEKK down-regulation of CYP4F11 does not occur. These data
clearly suggest that CYP4F11 down-regulation requires p65 or NF-"B.
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Figure 4.6. IMD-0354 inhibition of NF-!B releases inhibition of
CYP4F11 transcripts. HepG2 cells were transiently transfected with
CYP4F11 deletion promoter constructs 24 hours after being plated.
Cells were then co-treated with TNF-! and IMD-0354 (NF-"B
translocation inhibitor) 24 hours post transfection for 24 hours and
then luciferase activity was measured. Measuring Renilla luciferase
activity of co-transfected phRL-SV40 normalized the transfection
efficiencies.
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Figure 4.7. TNF-" and MEKK mediated down-regulation of
CYP4F11 promoter is NF-!B dependent: HepG2 cells were reverse
transfected with siRNA against p65 with lipofectamine RNAiMAX. 24
hours post transfection, HepG2 cells were transiently transfected with
CYP4F11 luciferase deletion promoter constructs. Cells were then
treated with TNF-! 24 hours post luciferase transfection for 24 hours
and then luciferase activity was measured. Measuring Renilla
luciferase activity of co-transfected phRL-SV40 normalized the
transfection efficiencies.
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Discussion
The ability for cytokines, prostaglandins and other inflammatory mediators
to alter the expression of many different CYPs has been the subject of many
different studies [61, 97, 104, 105]. The importance of this work stems from the
effects that changes in CYP levels have on the metabolism of many drugs, on the
homeostasis of steroid hormones and on the ability of CYPs to detoxify
xenobiotics. The effects of inflammation on CYP expression are varied, but the
predominant effect is that inflammatory cytokines suppress the gene expression of
most CYPs. In the current study we have presented a novel regulatory role for
CYP4F11 expression during an inflammatory response. We have shown that
activation of the NF-"B pathway by TNF-! stimulation or over-expression of MEKK
causes down-regulation of CYP4F11 transcripts. However, what makes this unique
is that the inhibition of native CYP4F11 is not seen in the presence of TNF-! after
24 hours (Figure 4.1) as was seen in this study and in a previous study [102]. We
believe this is due to the signal transduction properties of TNF-!. It is believed that
the c-Jun N-terminal Kinases (JNK) pathway and the NF-"B pathways are both
stimulated in the presence of TNF-!; however, they are competing forces [106].
The up-regulation of CYP4F11 mRNA in the presence of TNF-! is due to the
stimulation of the JNK pathway [102], however this is time dependent and does not
reach a level of significance until 24 hours after treatment as observed in our
laboratory. This was confirmed in the ChIP analysis where at 1 hour there was a
large increase in p65 bound CYP4F11 transcripts that remained constant at 24
hours.
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The inhibition seen in CYP4F11 promoter constructs is driven mainly by NF"B activation. We were able to show this in various experiments including inhibiting
translocation of NF-"B to the nucleus and then treating HepG2 cells with TNF-!
(Figure 4.1). This resulted in a large increase of transcripts leading us to believe
that although JNK is a strong stimulator of CYP4F11 expression, NF-"B may be
playing an inhibitory role. After determining that NF-"B inhibition caused a
decrease in promoter activity in our constructs (Figure 4.4) we then utilized
chemical inhibition (Figure 4.6) and protein knockdown (Figure 4.7) of NF-"B and
determined the effects on the promoter activity. We found that in those cases there
was either control level expression or over-expression of CYP4F11 gene. This led
us to believe that the down-regulation of CYP4F11 is NF-"B dependent. The cases
of over-expression can be explained by the activation of the areas in the promoter
region that have AP-1 binding sites which would create higher levels of expression
of CYP4F11 in the presence of JNK activation. This mechanism was described in a
recent paper published by our lab in Drug Metabolism and Disposition 2010 [102].
In short, JNK activation causes activation of AP-1 protein which regulates
expression through the AP1 binding site on a gene’s promoter. In the 1.7kb
CYP4F11 promoter construct there are five AP-1 binding sites positioned
throughout the promoter region and when TNF-! is present JNK signaling can still
occur and elicit regulation of the CYP4F11 promoter construct. Overall, this finding
is just one piece of a very complicated mix of regulatory networks that lead to the
regulation of CYP4F11, and with each finding the pieces of the puzzle are
beginning to fit. This is pictorially represented in Figure 4.8. Overall, we believe
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that this regulation of CYP4F11 may be an important mechanism of compensation
in cells. As most CYPs are down regulated during the inflammatory response it is
unique that CYP4F11 is up-regulated. CYP4F11 has the ability to compensate for
the metabolism profiles of CYP4F2 and CYP4F3A/B as these enzymes are downregulated during an inflammatory response. However this theory needs to be
tested further with functional studies that can show the effects of inflammatory
response on activity. This, in addition to regulatory sites found for CYP4F11, may
help investigators develop drug therapies to one or several regulatory sites to
modulate pathological inflammation.
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Figure 4.8. Summary of TNF-" Regulation of CYP4F11
Expression. Diagram of regulation of CYP4F11 expression. TNF-!
activates pathways for JNK and NF-"B, these two pathways
although both activated are able to regulate genes that oppose
each other. What we have found is that the longer TNF-! is present
and activating its receptor the more the JNK pathway is activated,
this activation up-regulates CYP4F11 expression, however other
signaling that can activate NF-"B would cause an inhibition of
CYP4F11.
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Chapter Five: Conclusions, Significance and
Future Directions
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Localization of CYP4Fs
!

Although work on the Cytochrome P450 4F family began in the 1990ʼs

there, is still more work that needs to be done to understand fully all the
characteristics of this family. This current work in identifying the mRNA level of
expression of the CYP4F family in different human tissues is novel in itself and is
an important step in translating what we have learned in the animal models to
human studies. While localizing and determining the relative quantities of the
CYP4Fs in the liver, lung, spleen, kidney, heart and brain are very important,
finding that these enzyme profiles change in the presence of inflammatory
mediators helps in understanding regulation of these enzymes. This is important
because it is the first time its been shown that human patient samples change
CYP4F expression levels in a disease state. It also demonstrates the importance
of animal model testing, where studies have shown that injury causes significant
changes in the CYP4F expression profile.
!

It is important to next examine the protein levels of each isoform in these

tissues. This has currently been a problem because of 1) the high homology
between the CYP4F family which leads to 2) lack of specific antibodies for each
isoform. This approach will show how the mRNA expression level relates to the
protein functional expression in tissues. Another approach that should be pursued
is identifying a specific inflammatory disease and obtain tissue samples from those
patients in order to compare them to a specified control to determine the exact
effects a known inflammatory disease model has on CYP4F expression and what
functionality gain or loss is associated with it.
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CYP4F11 expression in the brain
!

This research project identified the expression profile of the CYP4F family in

the brain, and found hat CYP4F11 was expressed at high quantities. Knowing that
CYP4F11 has a diverse substance specificity that ranges from xenobiotics to
endogenous compounds, makes this finding even more relevant and important. It
is important to note that the orbital frontal cortex is responsible for integrating
emotion with behavior and is the site of a large number of neurotransmitter
signaling processes. With the knowledge that 1) CYP4F11 is expressed at high
levels in this region and 2) that the expression is present in both the neurons, site
of neurotransmitter action, and glial cells, site or neuroinflammatory control, there
is the possibility that the enzyme may be a potential drug target for different mental
disease states affecting this region of the brain.
!

Future work studies should include additional brain regions. This study

focused on the orbital frontal cortex, but the addition of other regions is needed
because of the specificity that is seen in other CYPs expressed in the brain.
Functional studies of CYP4F11 in the frontal cortex would also be beneficial to
determine how this enzyme can function as a drug target.
NF-κB inhibits CYP4F11 expression
!

Work in our laboratory has focused on the regulation of the CYP4Fs during

an inflammatory response. We have focused on this because of the role CYP4Fs
play in decreasing inflammatory mediators such as leukotrienes and
prostaglandins. This current study determined that CYP4F11 is negatively
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regulated by the activation of NF-κB. The importance of this finding is that while
other research has shown that CYP4F11 is up-regulated by TNF-α stimulation this
current research determined that if NF-κB is blocked and cells are stimulated by
TNF-α there is a three fold increase of expression. As more work is done on the
role CYP4F11 has during an inflammatory response this information will be of use
in determining the link between inflammation, CYP4F11 and cell metabolism
function.

Conclusion
#

This research project has many parts that when placed together create a

picture of how CYP4Fs are expressed and how inflammatory mediators especially
TNF-α, play an important role in the regulation of this family of enzymes. We
believe that the expression of CYP4F2 and CYP4F3B at high levels across a
diverse array of tissues helps to create homeostasis in the body by regulating LTB4
levels and 20-HETE levels in their specific organs. As inflammatory response
signals infiltrate the tissue they are able to regulate the expression of these
enzymes so that the normal host defense mechanism can take place. In the
example of the liver presented in Chapter 2, inflammation increased CYP4F11
expression and the presence of CYP4F3B, but at the same time it caused a
decrease in CYP4F2 expression. These regulatory functions are necessary both
for the normal host defense process and then the subsequent return to normal
functional state. The reduction in CYP4F2 helps to keep LTB4 present at the site of
infection or injury so that neutrophils can be recruited to area. The increase in
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CYP4F11 and CYP4F3B helps to increase the levels of 20-HETE which has also
been associated with the presence of inflammation [107]. As all of this is taking
place during the pro-inflammatory state, the switch to the anti-inflammatory stage
leads to a time dependent increase in CYP4F2, which provides greater LTB4
metabolism while also decreasing the presence of CYP4F3B and CYP4F11
expression. This hypothesis of regulatory controls still needs further elaboration,
but the work done in this current research project has added new pieces to the
puzzle.
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